Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
The Big Apple today is playing host to the world debut of the all-new 2017 Kia Cadenza at the New York International Auto Show. The stunningly beautiful Cadenza improves upon all the elements that made its predecessor an award-winning success, boasting a precisely crafted cabin, cutting edge technology for connectivity and driver assistance, a stronger body structure, and powertrain enhancements for a more premium experience behind the wheel.
“The new Cadenza adds an extra dose of excitement to the large-car segment with its striking, aggressively handsome looks and premium refinements,” said Orth Hedrick, vice president of product planning, Kia Motors America. “Everything you see and touch in the Cadenza’s cabin has been improved, but it’s underneath where the Cadenza truly shines with a stiffer and lighter chassis, eight-speed transmission and vastly improved driving dynamics.”
The second-generation Cadenza is set to go on-sale in late 2016, and pricing will be announced closer to the vehicle’s launch date.
To view the multimedia release go to:
http://www.multivu.com/players/English/7731856-2017-kia-cadenza-nyias/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
The National Meningitis Association (NMA) today announced the launch of a new educational initiative in collaboration with Sanofi Pasteur, the vaccines division of Sanofi, about the importance of the Centers for Disease Control and Prevention’s (CDC’s) recommended second dose of the meningococcal meningitis vaccine (MenACWY) for adolescents at age 16. The 16 Vaccine (The16Vaccine.org) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.
To view the multimedia release go to:
https://www.multivu.com/players/English/8385951-national-meningitis-association-the-16-vaccine/
https://www.desertsafaritours.com/
This video is about sunrise desert safari Dubai. For the thrill seekers planning to pack their day with new adventures, the early morning sunrise desert safari is a great way to load their day with adventure. They can plan their daily dose of adventure and start off early morning with the desert safari at sunrise. If you start off your thrill activities from sunrise, you will be able to plan out plenty of activities on the same day.
Despite a decrease in lung function as you age, recent studies by researchers have concluded that to slow down this decrease lung health, you need to continue to give yourself a good dose of,
Vitamin D
Vitamin C
Magnesium
Vitamin K
